Abstract:disease (CHD) or atherosclerosis is elevated levels of serum cholesterol. Recent clinical trials and studies have confirmed that lowering of low-density lipoprotein (LDL) cholesterol is related to a reduction in CHD risk. The reduction of serum cholesterol levels has mainly been accomplished by inhibiting cholesterol biosynthesis or by blocking the absorption of dietary cholesterol. Statins, such as pravastatin, that effectively inhibit cholesterol biosynthesis are HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase) inhibitors and are widely prescribed in the treatment of hypercholesterolemia. Several squalene synthesis inhibitors have been also reported. SCH-48461 (a trans-azetidinone) and 4 ,6 -bis((2-fluorophenyl)carbamoyl) b-O-cellobioside (a steriodal glycoside) have recently been reported to be cholesterol absorption inhibitors. Phytosterols, or plant sterols, are an interesting class of compound due to their application and biological activities. The phytosterols found most frequently in nature are b-sitosterol, campesterol, and stigmasterol. It has been known that they inhibit the absorption of dietary and endogenously produced cholesterol from the small intestine, reducing blood cholesterol concentrations both in animal models and in humans. b-Sitosterol and b-sitostanol fatty acid esters were recently commercialized as food additives to reduce serum cholesterol levels. A novel hydrophilic phytostanol analogue, FM-VP4, was also developed to reduce serum cholesterol levels. However, even with the current therapeutic agents, it is not easy to achieve proper plasma cholesterol levels without side effect. Therefore the discovery of more effective, well-tolerated agents that reduce high cholesterol levels is needed. We here report the synthesis and interesting pharmacologic properties of novel succinamic acid ester derivatives that are bsitosterol analogues, compounds 1 and 2, that have the ability to lower plasma cholesterol levels and that can be more effective cholesterol-lowering alternatives to b-sitosterol and bsitostanol fatty acid esters. Chemistry The synthesis of b-sitosterol analogues 1 and 2 are summarized Chart 1. The b-sitosterol-3-hemisuccinate ester 1 was prepared by the reaction of b-sitosterol and succinic anhydride in toluene with a catalytic amount of DMAP. The chlorination of the resulting acid compound 1 with SOCl2 and then direct amination with appropriate amines afforded N-substituted succinamic acid b-sitosteryl ester derivatives 2. Compounds 2 were also synthesized in 76—92% yields by the reaction of 1 with methyl chloroformate, followed by amination of the activated intermediate. Interestingly, compound 2a (DANA87) was also easily obtained in one step by the direct addition of b-sitosterol to dicyclohexylcarbodiimide (DCC) in 80% yield. It was considered that compound DANA87 was prepared by slow thermal degradation of the May 2004 Notes Chem. Pharm. Bull. 52(5) 597—601 (2004) 597

SK&F 97426-A a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster

Absolute Oral Bioavailability of Fenofibric Acid and Choline Fenofibrate in Rats Determined by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry

Biopolymer-based Sequestrants for Lowering Cholesterol: Structures, in Vitro Bile Acid Anion Binding Effects, and Interaction Mechanisms

Effect of treatment with a bile-sequestering agent (Secholex) on intestinal absorption, duodenal bile acids, and plasma lipids

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Serum Cholesterol-Lowering Activity of β-Sitosterol Laurate Is Attributed to the Reduction of Both Cholesterol Absorption and Bile Acids Reabsorption in Hamsters

Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives

Cholesterol side chain analogs but not its ether analogs possess cholesterol-lowering activity.

Effect of Berberine on Promoting the Excretion of Cholesterol in High-Fat Diet-Induced Hyperlipidemic Hamsters

Plasma Cholesterol-Lowering Activity of Dietary Dihydrocholesterol in Hypercholesterolemia Hamsters

Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB

Ezetimibe Enhances Macrophage-to-Feces Reverse Cholesterol Transport in Golden Syrian Hamsters Fed a High-Cholesterol Diet

Novel Guanidinium-Functionalized Stigmasterol for Bile Salt Binding and Serum Cholesterol Reduction: Synthesis, Interaction Mechanisms, and In Vivo Function

Marine Chitosan-Oligosaccharide Ameliorated Plasma Cholesterol in Hypercholesterolemic Hamsters by Modifying the Gut Microflora, Bile Acids, and Short-Chain Fatty Acids

Effect of a New b-Sitosterol Analogue on Plasma Lipid Concentrations in Rats 1 )

Plasma Cholesterol-Raising Potency of Dietary Free Cholesterol Versus Cholesteryl Ester and Effect of Β-Sitosterol.

High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits

Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 knockout mice with a humanized bile acid composition

In vitro accumulation of thyroid hormones by cultured rat hepatocytes and the biliary excretion of iodothyronines in rats treated with a novel histamine H2-receptor antagonist

Cholesterol-lowering Effect of Bile Salt Hydrolase from Alactobacillus Johnsoniistrain Mediated by FXR Pathway Regulation

Blockage of Hydroxyl Group Partially Abolishes the Cholesterol-Lowering Activity of Β-Sitosterol